Ayşegül ERTİNMAZ ÖZKAN, Nurhayat ÖZKAN SEVENCAN

Gender-dependent relationship between metabolic syndrome and HOMA-IR index in patients with impaired fasting glucose

Aim: This study aimed to assess whether metabolic syndrome (MetS) criteria varied by gender and whether the homeostatic model assessment of insulin resistance (HOMA-IR) index could be used as a new MetS predictor. Materials and Methods: We performed a standard oral glucose tolerance test (OGTT) in 316 patients with impaired fasting glucose (IFG) and investigated the presence of impaired glucose tolerance (IGT), type 2 diabetes mellitus (T2DM), and MetS. Results: We found that MetS was higher in females than males. The obesity rate was 57.0% and 36.8% for females and males, respectively. Of the patients who reached stage 3 obesity,13.4% were females and 0.9% were males. The HOMA-IR score was not an independent predictor for MetS. However, sensitivity was 91% and specificity was 100% for the cut-off value of HOMA-IR ≥ 2.38 in diabetic females with MetS. Abdominal obesity (91.2%), hyperglycemia (81.5%), hypertension (71.8%), hypertriglyceridemia (62.0%), and low high-density lipoprotein (HDL) (57.8%) were found in MetS patients. Conclusion: Abdominal obesity and impaired glucose metabolism are powerful predictors demonstrating the presence of MetS. Females are at greater risk than males for obesity, T2DM, and MetS. Although the HOMA-IR score is not a new MetS predictor, it may be an effective indicator of the combination of MetS and diabetes in females.

PDF

___

1. Alberti K, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; national heart, lung, and blood institute; American heart association; world heart federation; international atherosclerosis society; and international association for the study of obesity. Circulation 2009;120:1640-5.
2. National CEPN. Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143.
3. Kurotani K, Miyamoto T, Kochi T, et al. Metabolic syndrome components and diabetes incidence according to the presence or absence of impaired fasting glucose: The Japan Epidemiology Collaboration on Occupational Health Study. J Epidemiol 2017;27:408-12.
4. Nakanishi N, Takatorige T, Fukuda H, et al. Components of the metabolic syndrome as predictors of cardiovascular disease and type 2 diabetes in middle-aged Japanese men. Diabetes Res Clin Pract 2004;64:59-70.
5. Sattar N, Gaw A, Scherbakova O et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003;108:414-9.
6. Wilson PW, D’Agostino RB, Parise H et al. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation 2005;112:3066- 72.
7. Wannamethee SG, Shaper AG, Lennon L, et al. Metabolic syndrome vs Framingham Risk Score for prediction of coronary heart disease, stroke, and type 2 diabetes mellitus. Arch Intern Med 2005;165:2644-50.
8. Heianza Y, Arase Y, Fujihara K, et al. Screening for prediabetes to predict future diabetes using various cutoff points for HbA1c and impaired fasting glucose: the Toranomon Hospital Health Management Center Study 4 (TOPICS 4). Diabet Med 2012;29:279-85.
9. Levitzky YS, Pencina MJ, D’Agostino RB, et al. Impact of impaired fasting glucose on cardiovascular disease: the Framingham Heart Study. J Am Coll Cardiol 2008;51:264-70.
10. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988;37:1595-607.
11. Smiley T, Oh P, Shane LG. The relationship of insulin resistance measured by reliable indexes to coronary artery disease risk factors and outcomes--a systematic review. Can J Cardiol 2001;17:797-805.
12. von Bibra H, Saha S, Hapfelmeier A, et al. Impact of the triglyceride/high-density lipoprotein cholesterol ratio and the hypertriglyceremic-waist phenotype to predict the metabolic syndrome and insulin resistance. Horm Metab Res 2017;49:542-9.
13. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 2004;27:1487-95.
14. Association AD. Standards of medical care in diabetes—2013. Diabetes Care 2013;36:11-66.
15. Expert Panel on Detection E. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001;285:2486.
16. Bonora BM, Marescotti M, Marcuzzo G, et al. Synergistic interactions among metabolic syndrome components and homeostasis model assessment of insulin resistance in a middle-aged general population over time. Metab Syndr Relat Disord 2015;13:171-8.
17. Alberti KGM, Zimmet P, Shaw J. The metabolic syndrome—a new worldwide definition. Lancet 2005;366:1059-62.
18. Satman I, Yilmaz T, Sengul, A et al. Population-based study of diabetes and risk characteristics in Turkey: results of the turkish diabetes epidemiology study (TURDEP). Diabetes Care 2002;25:1551-6.
19. Satman I, Omer B, Tutuncu Y, et al. Twelve-year trends in the prevalence and risk factors of diabetes and prediabetes in Turkish adults. Eur J Epidemiol 2013;28:169-80.
20. Sevencan NÖ, Özkan AE. 3-Year Obesity and Diabetes Prevalence of a University Hospital: Retrospective Analysis of Adult and Childhood Data. Türk Diyab Obez 2019;3:31-6.
21. Djalalinia S, Moghaddam SS, Sheidaei A, et al. Patterns of Obesity and Overweight in the Iranian Population: Findings of STEPs 2016. Front Endocrinol (Lausanne) 2020;11.
22. Al-Raddadi R, Bahijri SM, Jambi HA, et al. The prevalence of obesity and overweight, associated demographic and lifestyle factors, and health status in the adult population of Jeddah, Saudi Arabia. Ther Adv Chronic Dis. 2019;10:2040622319878997.
23. Khosravi-Boroujeni H, Sarrafzadegan N, Sadeghi M, et al. Determinants of Changes in Metabolic Syndrome Components in a 12-Year Cohort of Iranian Adults. Metab Syndr Relat Disord 2019;17:120-7.